Outsmarting cancer

Probody® therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, their substrates are designed to be cleaved, removing their masks and activating them to bind to their tumor targets, potentially turning the disease against itself.

With Probody therapeutics, we have the potential to:

  • Create or widen the therapeutic window—the range of a drug’s dosage that is effective without causing unacceptable toxicity
  • Enable new combinations previously not possible due to toxicities
  • Expand the universe of drug targets previously considered “undruggable” due to the target’s presence on health tissues
  • Make new treatment options possible, so that more patients can benefit

More information about protease biology can be found in our fact sheet.

Current treatments suffer from limited therapeutic window Probody therapeutics can help extend the therapeutic window
% of patients responding Dose of drug
Therapeutic Window Current Therapeutic Window Effects

Designed to selectively activate in the presence of cancer

Probody® therapeutics have been intentionally designed to bind selectively to tumors, and not to healthy tissue, with the goal of minimizing toxicity and creating safer, more effective cancer therapies. This revolutionary approach and its resulting Probody drug candidates are based on a deep understanding of protease biology.

Parental Antibody

A pioneering antibody prodrug technology.

Healthy Tissue

The “masking” peptide is designed to limit the ability of Probody therapeutics to bind to healthy tissue—thereby helping to minimize toxicities.

Diseased Tissue

In the tumor environment, protease enzymes are expected to cleave the substrate, removing the “mask” and activating the Probody therapeutic to bind to its target on cancer cells.

Next generation of targeted antibody therapeutics.

A versatile platform

Our highly versatile Probody® platform has potential utility across the most compelling antibody therapeutic modalities: Immunotherapies, antibody drug conjugates, T cell engaging bispecifics, and cytokine therapy.

Immune modulators/
checkpoint inhibitors
Immune modulators/</br>checkpoint inhibitors
PD-L1 (CX-072)
CTLA-4 (BMS-986249)
CTLA-4 (BMS-986288)
drug conjugates
Antibody</br>drug conjugates
CD166 (CX-2009)
CD71 (CX-2029)
EpCAM (CX-2043)
T-cell bispecifics
T-cell bispecifics
EGFR-CD3 (CX-904)
Multiple other programs
in development
Multiple other programs
in development

Xtensive library of scientific publications & presentations

Data for our Probody® platform and therapeutics has been published in peer-reviewed articles and presented at medical congresses.

"I'm excited to be here every day to see how our technology will perform in the clinic and to really improve people's lives."

—Mike Winter